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ERApoB-crescent, an endoplasmic reticulum (ER)-lipid droplet amalgamation structure, is a useful
marker to indicate aberrant lipidated apolipoprotein B accumulation in the hepatocyte ER. Blockade
of the ER-to-Golgi transport by either vesicle transport inhibitors or dominant-negative Arf1 caused
a signiﬁcant increase in ApoB-crescents. However, a low concentration of Brefeldin A induced the
same result without affecting protein secretion, suggesting ADP-ribosylation as an additional
mechanism. ADP-ribosylation inhibitors not only suppressed the increase of ApoB-crescents, but
also rapidly dissolved existing ApoB-crescents. These results implicate the involvement of ADP-ribo-
sylation in the ApoB-crescent formation and maintenance process at the ER.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Apolipoprotein B-100 (ApoB) is a protein that constitutes very
low-density lipoproteins (VLDL). In hepatocytes, ApoB is lipidated
cotranslationally to form pre-VLDL, which thereafter acquires
additional lipids to become mature VLDL. Because the VLDL
concentration in the blood needs to be strictly controlled to
maintain systemic lipid metabolism, it is important to understand
the regulatory mechanism of VLDL secretion.
The VLDL secretion from hepatocytes is regulated mainly by
ApoB protein degradation [1]. If the co-translational lipidation does
not occur properly, nascent ApoB is dislocated from the Sec61
translocon to the cytoplasm, ubiquitinated, and degraded by
proteasomes [2]. In addition to this well-characterized mechanismto degrade poorly-lipidated ApoB, ApoB after lipidation is also
subjected to intracellular degradation [2–6]. In previous studies,
we deﬁned a degradation pathway of lipidated ApoB at the
juncture of ER and lipid droplets (LD) and showed that Derlin-1
and UBXD8 play critical roles [7,8]. When this ApoB degradation
pathway is suppressed by proteasome inhibition, docosahexaenoic
acid (DHA), UBXD8 knockdown, or other methods, a unique ER-LD
amalgamation structure called an ‘ApoB-crescent’ increased
signiﬁcantly [7,8]. These ﬁndings along with other results
suggested that the ApoB-crescent formation is induced by an
abnormal accumulation of lipidated ApoB in the ER lumen.
Conversely, ApoB-crescents are regarded as a convenient way to
monitor the lipidated ApoB degradation process.
In the present study, we explored the mechanism of ApoB-cres-
cent formation in detail. We hypothesized that if an increase in
lipidated ApoB induces ApoB-crescents, then blockade of the ER-
to-Golgi transport should also increase their numbers. To test this
hypothesis, we applied several different methods to suppress the
secretory pathway and found that all of them indeed increased
ApoB-crescents. Surprisingly, brefeldin A (BFA) at a low concentra-
tion increased ApoB-crescents without signiﬁcantly affecting
secretion. Because this BFA effect was repressed by ADP-ribosyla-
tion inhibitors, we concluded that an unknown target(s) of ADP-
ribosylation is involved in the degradation process of lipidated
ApoB. The results are discussed with regards to the mechanism
of ApoB-crescent formation.
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2.1. Cells and transfection
Huh7, HepG2, and 3Y1 cells were used. When appropriate, cells
were incubated in medium containing 10 lM N-acetyl-L-leucyl-L-
leucyl-L-norleucinal (ALLN) (Sigma–Aldrich) to inhibit proteasomal
functions. Oleic acid (OA) and DHA (Sigma–Aldrich) were
complexed with fatty acid-free BSA (Wako) at a molar ratio of
6:1 and applied at a ﬁnal fatty acid concentration of 0.4 mM.
2.2. Plasmids
pcDNA3.1(+)/HA tagged-human Arf1(WT) and Arf1(T31N) were
kindly donated by Dr. Naoko Morinaga (Chiba University). Human
CtBP1-S/BARS cDNA was obtained by reverse transcription and
cloned to the pEGFP-C2 vector (Clontech).
2.3. Subcellular fractionation
Cells were disrupted by nitrogen cavitation and subjected to a
sucrose density gradient ultracentrifugation [9]. Fractions were
precipitated with 10% trichloroacetic acid, dissolved in the sample
buffer, and analyzed by Western blotting.
2.4. Immunoﬂuorescence microscopy and data analysis
Cells were ﬁxed with 3% formaldehyde and permeabilized
either with 0.01% digitonin or with 0.1% Triton X-100. LDs and
nuclei were stained with BODIPY493/503 (Invitrogen) and 4,6-
diamidino-2-phenylindole (DAPI) (Sigma–Aldrich), respectively.
To analyze effects on ApoB-crescents, at least 10 pictures were
randomly taken, and the ratio of ApoB-crescent-positive cells was
quantiﬁed. The results from three independent experiments were
averaged, and the statistical difference from the control was
examined using the Student’s t-test.
2.5. Electron microscopy
Cells cultured on coverslips were ﬁxed with 2.5% glutaralde-
hyde in 0.1 M sodium cacodylate buffer and post-ﬁxed in a mixture
of 1% osmium tetroxide and 0.1% potassium ferrocyanide in the
same buffer.
2.6. Microsomal triglyceride transfer protein (MTP) activity assay
The MTP activity of mouse liver tissue homogenate (50 lg
protein), HepG2 cells (50 lg protein), and 1 lg puriﬁed MTP was
measured using the ﬂuorescence assay as described [10].
3. Results
3.1. ApoB-crescents increased signiﬁcantly by blockade of the ER-to-
Golgi transport
The ApoB-crescent is an ER-LD amalgamation structure, which
is recognized as crescent-shaped ApoB labeling around LDs by
immunoﬂuorescence microscopy [9]. To examine whether block-
ade of the ER-to-Golgi transport increases ApoB-crescents, we
tested three vesicle transport inhibitors that work by different
mechanisms. BFA down-regulates COPI vesicle formation by sup-
pressing the GDP/GTP exchange activity of Arf1-GEF [11,12],
whereas Exo1 accelerates GTP hydrolysis through the activation
of Arf1-GAP [13]. NDGA has been suggested to modulate thedynein-dynactin-related process [14] and to disrupt cisternal
organization of the Golgi complex [15]. When Huh7 cells were
treated with these reagents, secretion of ApoB was virtually
abolished, but the intracellular amount of ApoB did not decrease
signiﬁcantly (Fig. 1A), suggesting an increase of ApoB in the ER.
Under this condition, a signiﬁcant increase of ApoB-crescents was
observed (Figs. 1B, C).
We also tested the effect of transient expression of Arf1(T31N),
the dominant-negative form of Arf1 that down-regulates the ER-
to-Golgi transport [16]. The ApoB-crescent formation was in-
creased in cells expressing Arf1(T31N), but not in cells expressing
wild-type Arf1 or EGFP alone (Fig. 1D).
The increase of ApoB-crescents by the above treatments was
completely inhibited when MTP inhibitor (MTPi; BAY13-9952 at
100 nM) was given simultaneously (data not shown), conﬁrming
that lipidated ApoB is responsible for the ApoB-crescent formation.
The result corroborated that blockade of the ER-to-Golgi transport
caused accumulation of lipidated ApoB in the ER and thereby
increased ApoB-crescents.
3.2. A low concentration of BFA increased ApoB-crescents without
inhibiting secretion
In the above experiment, cells were treated with BFA for 1 h at a
concentration of 5 lg/ml. This condition is generally used to block
the ER-to-Golgi transport. We found, however, that ApoB-crescents
increased even when BFA was applied to Huh7 cells at much lower
concentrations, i.e., 5–10 ng/ml (Fig. 2A). In cells treated with
10 ng/ml BFA for 12 h, the Golgi delineated by immunoﬂuores-
cence labeling of GM130 showed disintegration (Fig. 2B) and ApoB
and transferrin secretion decreased (Fig. 2C), but neither of these
changes were observed in cells treated with 5 ng/ml BFA for 12 h
(Figs. 2B, C). It was further conﬁrmed that ApoB-crescents induced
to form by 5 ng/ml BFA take a similar ultrastructure to those
caused by proteasomal inhibition or DHA [7] (Fig. 2D). This result
suggested that BFA does not increase ApoB-crescents simply by
blocking the ER-to-Golgi transport, but that other mechanisms
may be involved.
3.3. ADP-ribosylation inhibitors suppressed ApoB-crescent formation
Besides inhibition of Arf1-GEF, BFA is known to increase ADP-
ribosylation of several proteins [17,18]. To test whether ADP-ribo-
sylation is related to the ApoB-crescent formation, we examined
the effect of three ADP-ribosylation inhibitors: MIBG, which is spe-
ciﬁc to mono-ADP-ribosylation [19,20], and coumarimycin A1 and
NAM, which are effective for both mono- and poly-ADP-ribosyla-
tion [21]. When Huh7 cells were treated for 6 h with 5 lg/ml
BFA in the presence of one of the ADP-ribosylation inhibitors,
ApoB-crescent formation was suppressed signiﬁcantly (Figs. 3A,
B). This result indicated that the effect of BFA on the ApoB-crescent
formation was exerted mainly through facilitating ADP-ribosyla-
tion. Because MIBG is thought to be most speciﬁc to mono-ADP-
ribosylation among the three reagents [21], the following experi-
ments were mainly performed using MIBG, but the other two
inhibitors were also tested in most cases.
MIBG also inhibited the increase of ApoB-crescents that was
induced by other reagents. In the presence of MIBG, either prote-
asomal inhibition with 10 lM ALLN or treatment with 0.4 mM
DHA failed to increase ApoB-crescents (Fig. 3C). The inhibitory
effect of MIBG on ApoB-crescent formation was similar even when
cells were treated with a mixture of ALLN and 3-methyladenine to
suppress both autophagy and proteasomes (Fig. 3D).
The effect of ADP-ribosylation inhibition on ApoB was further
examined by western blotting of subcellular fractions (Fig. 3E). In
Huh7 cells treated with 10 lM ALLN alone for 12 h, a signiﬁcant
Fig. 1. Blockade of the ER-to-Golgi transport increased the number of ApoB-crescents. (A) Effect of vesicular transport inhibitors on intracellular and secreted ApoB. Huh7
cells were treated with 5 lg/ml BFA, 100 lM Exo1, or 30 lM NDGA for 4 h. Cell lysates and the culture media were subjected to Western blotting. ApoB secreted into the
culture medium was reduced signiﬁcantly by any of the reagents, whereas the decrease in intracellular ApoB was relatively small. (B) BFA caused a signiﬁcant increase in
ApoB-crescents. Huh7 cells treated with 5 lg/ml BFA for 1 h were labeled for ApoB (red), LD (green), and DNA (blue). Arrowheads indicate ApoB-crescents that are observed
as a crescent-shaped or circular ApoB labeling around LDs. Bar, 10 lm. (C) Vesicle transport inhibitors increased ApoB-crescents. In Huh7 cells treated with 5 lg/ml BFA,
100 lM Exo1, or 30 lMNDGA for 6 h, the ratio of ApoB-crescent-positive cells increased signiﬁcantly. (D) Overexpression of a dominant-negative Arf1, Arf1(T31N), increased
ApoB-crescents. Huh7 cells were transfected with cDNA of either EGFP alone, HA-tagged wild-type Arf1 [HA-Arf1(WT)], or HA-tagged Arf1(T31N), and examined one day
later. The introduced proteins (red) along with ApoB (green) and DNA (blue) are shown. Arrowheads indicate ApoB-crescents. Please note that only ApoB in ApoB-crescents is
labeled when cells are permeabilized with digitonin [9]. Bars, 10 lm.
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mulation of lipidated ApoB in ApoB-crescents [7]. In contrast, when
Huh7 cells were treated for 12 h with both 10 lM ALLN and 25 lM
MIBG, ApoB in the LD fraction was negligible, consistent with the
decrease of ApoB-crescents in the MIBG-treated cell (Fig. 3C). Sim-
ilar results were obtained with the other ADP-ribosylation inhibi-
tors (data not shown).
In addition, MIBG caused a rapid decrease in the number of
existing ApoB-crescents. ApoB-crescents that had formed by treat-
ment with 10 lM ALLN for 6 h decreased signiﬁcantly within 1 h
after MIBG was applied (Fig. 3F). Consistent with this result, the
amount of ApoB in the LD fraction of the ALLN-treated cells was re-
duced to a negligible level by treatment with 25 lM MIBG for 1 h
(Fig. S1).
Several results indicated that MIBG did not affect the amount
of LDs. First, MIBG did not affect the amount of ADRP (perilipin2),
an authentic LD marker protein, in the LD fraction (Fig. 3E).
Second, MIBG did not inﬂuence de novo LD formation that was
induced by fatty acids (Fig. S2). These results suggested that
ADP-ribosylation inhibitors suppressed the process of ApoB-
crescent formation per se without affecting the LD-related lipid
metabolism.
It was also conﬁrmed that treatment with MIBG did not de-
crease either the mRNA or the protein level of ApoB in the cell
(Figs. S3A, B). On the other hand, even when transcription was
inhibited with actinomycin D, secretion of ApoB was not affected
after incubation for up to 6 h (Fig. S3C). The result indicated that
the effect of MIBG on ApoB-crescents was exerted by a mechanism
unrelated to the ApoB expression.3.4. MIBG suppressed ApoB-crescent formation without affecting the
MTP activity
MTP is critical for the assembly and secretion of apoB-contain-
ing lipoproteins and its inhibition reduces ApoB secretion [22]. We
have previously shown that MTP inhibition suppresses the ApoB-
crescent formation by blocking ApoB lipidation [7]. The drastic
reduction of ApoB-crescents by ADP-ribosylation inhibitors may
have been caused because the inhibitors suppressed the MTP
activity by an unknown mechanism. To address this possibility,
the effect of ADP-ribosylation inhibitors on the MTP activity was
examined by an in vitro assay. MIBG (25 or 100 lM) or NAM (10
or 30 mM) did not decrease the lipid transfer activity when mouse
liver tissue homogenate was used to assess MTP activity (Fig. 4A).
Similarly, MIBG and NAM neither reduced MTP activity in either
HepG2 cell lysates or the puriﬁed protein (Fig 4A). Rather, MIBG in-
creased the triglyceride transfer activity of MTP in vitro, but
whether it induced the same effect in cells needs to be examined
in a separate study. Further, we studied the effects of MIBG and
NAM on MTP activity using different amounts of liver tissue
homogenates. MIBG increased, but NAM had no effect, on MTP
activity (Fig. 4A). It was conﬁrmed that MIBG and NAM had no
effect on blank and total ﬂuorescent measurements (Fig. S4). Thus,
MIBG and NAM do not reduce MTP activity.
Consistent with the above result, the effect of MIBG on ApoB-
crescents was clearly different from that of an MTPi, BAY13–
9952. MIBG inhibited the increase of ApoB-crescents induced by
either ALLN or DHA (Fig. 3C and D), whereas BAY13–9952
suppressed the increase of ApoB-crescents induced by ALLN, but
Fig. 2. BFA at low concentration increased ApoB-crescents without affecting ApoB secretion. (A) Treatment with BFA at 5–10 ng/ml for 12 h caused a signiﬁcant increase in
ApoB-crescents. ApoB (red) and LD (green) were labeled. ApoB-crescents are indicated by arrowheads. Bar, 10 lm. (B) The Golgi showed structural disintegration in cells
treated with 10 ng/ml BFA for 12 h (left), but not in cells treated with 5 ng/ml BFA for 12 h (right). GM130, a Golgi matrix protein, was labeled. Bars, 10 lm. (C) Secretion of
both ApoB and transferrin was decreased with 10 ng/ml BFA but not with 5 ng/ml BFA. The culture media were collected 24 h or 48 h after the BFA addition. (D) Electron
microscopy of ApoB-crescents in cells treated with 5 ng/ml BFA for 12 h. The LD-ER amalgamation structures were frequently observed (arrow). The ER cistern constituting
the ApoB-crescent was relatively wide in many cases. Bar, 0.5 lm.
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reduced existing ApoB-crescents quickly (Fig. 3F), whereas
BAY13-9952 did not (Fig. 4C). Electron microscopy conﬁrmed that
the LD-associated ER cistern of existing ApoB-crescents shrank and
eventually disappeared with the MIBG treatment (data not shown).
The results indicated that the effect of MIBG on the ApoB-crescent
was not due to suppression of the MTP activity.
4. Discussion
VLDL secretion from hepatocytes is regulated mainly by
modulating intracellular ApoB degradation [1]. The degradation
of poorly-lipidated nascent ApoB has been studied extensively,but the mechanism whereby ApoB is processed after lipidation
is less well understood [2–6]. In a series of studies, we charac-
terized an LD-resident mechanism whereby lipidated ApoB is
degraded and showed that UBXD8 and Derlin-1 play critical
roles in this process [7,8,23]. Importantly, abnormal accumula-
tion of lipidated ApoB in the ER lumen was found to form a
unique ApoB-crescent structure that can be easily observed
using immunoﬂuorescence microscopy [9]. This structure in-
creased signiﬁcantly when degradation of lipidated ApoB was
abrogated, and it was totally abolished by MTP inhibition [7].
These results indicate that ApoB-crescents can be used as a
speciﬁc indicator to show abnormalities in the post-lipidation
process in the ER.
Fig. 3. ADP-ribosylation inhibitors decreased the number of ApoB-crescents. (A) The increase of ApoB-crescents induced by BFA was suppressed by MIBG. Huh7 cells were
cultured for 6 h in the presence of 5 lg/ml BFA with or without 100 lM MIBG. The cells were labeled for ApoB (red) and LD (green). ApoB-crescents are indicated by
arrowheads. Bars, 10 lm. (B) ADP-ribosylation inhibitors suppressed the increase of ApoB-crescents induced by BFA. Huh7 cells were treated with 5 lg/ml BFA for 6 h and the
effect of 100 lM MIBG, 100 lM coumermycin A1, and 30 mM NAM on the ratio of ApoB-crescent-positive cells was quantiﬁed. (C) MIBG suppressed the increase of ApoB-
crescents induced by either ALLN or DHA. Huh7 cells were treated for 6 h with 10 lM ALLN (a) or 0.4 mM DHA (b) in the presence of 0, 25, or 100 lM MIBG. (D) MIBG
suppressed the increase of ApoB-crescents induced by simultaneous inhibition of proteasomes and autophagy. Huh7 cells were treated for 6 h with both 10 lM ALLN and
10 mM 3-MA with or without 25 lM MIBG. (E) The amount of ApoB in the LD fraction decreased signiﬁcantly by MIBG. Huh7 cells were cultured for 12 h in the presence of
10 lM ALLN with or without 100 lM MIBG. Fractions obtained by sucrose density-gradient centrifugation were subjected to Western blotting. ApoB in the LD fraction
(fraction #1) decreased signiﬁcantly in cells treated with MIBG (left panel). The ADRP reactivity conﬁrmed that equivalent amounts of LDs were loaded for the two samples
(right panel). (F) MIBG decreased existing ApoB-crescents within 1 h. Huh7 cells were ﬁrst treated with 10 lM ALLN for 6 h to induce ApoB-crescents, and then incubated
with 0, 25, or 100 lM MIBG in the continual presence with ALLN.
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was found to increase signiﬁcantly in the following conditions
[7–9,24]: (1) inhibition of protein degradation by proteasomes or
autophagy, (2) suppression of the functionality of UBXD8 or
Derlin-1, (3) inhibition of the ER chaperone related to ApoB folding,
and (4) acceleration of the production of lipidated ApoB by fatty
acids. In the present study, we showed that blockade of the ER-
to-Golgi vesicular transport by any means increases the number
of ApoB-crescents signiﬁcantly. These results support ourcontention that ApoB-crescents indicate aberrant accumulation of
lipidated ApoB in the ER.
However, it was unexpected that BFA at low concentrations
increased ApoB-crescents without signiﬁcantly suppressing pro-
tein secretion. The ER-to-Golgi transport may be slightly af-
fected even by low concentrations of BFA, but the prominent
inhibitory effect of ADP-ribosylation inhibitors indicate that
BFA causes the increase of ApoB-crescents by activating ADP-
ribosylation.
Fig. 4. MIBG did not affect the MTP activity. (A) Neither MIBG nor NAM inhibited the MTP activity. The in vitro ﬂuorescence assay for the lipid transfer activity using mouse
liver tissue homogenate (a, d, e), HepG2 cell lysate (b), or puriﬁed MTP (c). The effect of MIBG (25 lM or 100 lM) and NAM (10 mM or 30 mM) was examined. The validity of
the assay was conﬁrmed by the signiﬁcant suppression of the activity in the presence of an MTPi (0.06 lM BMS200150). The assay was done using triplicate samples. (B) MTPi
suppressed increases in ApoB-crescents induced by proteasome inhibition but not by DHA. Huh7 cells were treated for 6 h with 10 lM ALLN or 0.4 mM DHA with or without
100 nM BAY13–9952. (C) MTPi did not affect existing ApoB-crescents. Huh7 cells were treated with 10 lMALLN for 6 h, and then treated for an additional 1 h with or without
BAY13-9952 in the continuous presence of ALLN.
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formation? First, we suspected that ADP-ribosylation inhibitors
may have suppressed MTP activity nonspeciﬁcally, but this pos-
sibility was refuted by the in vitro MTP assay (Fig. 4A). Second,
down-regulation of ApoB protein expression was not likely
because the cellular ApoB was not changed signiﬁcantly byADP-ribosylation inhibitors (Figs. 3E and S3B). Third, accelera-
tion of protein degradation by proteasomes or autophagy
may not be involved because ADP-ribosylation inhibitors sup-
pressed ApoB-crescent formation even when both degradation
pathways were inhibited (Fig. 3D). Fourth, acceleration of
secretion is also unlikely, because ApoB-crescent formation
3702 Y. Ohsaki et al. / FEBS Letters 587 (2013) 3696–3702was suppressed even in the presence of a high concentration of
BFA (Fig. 3A). Thus, ADP-ribosylation inhibition appears to sup-
press ApoB-crescent formation even though lipidated ApoB was
present in the cell.
Currently, the mechanism by which ADP-ribosylation inhibitors
suppress ApoB-crescent formation is unknown. An important clue
to elucidate the mechanism is the fact that ADP-ribosylation
inhibitors rapidly reduced the number of existing ApoB-crescents
(Fig. 3E), an effect that was not observed with MTPi or other
reagents (Fig. 4B). This result suggests that inhibition of ADP-ribo-
sylation facilitates the degradation or export of lipidated ApoB out
of the ER via a non-canonical pathway. Another non-exclusive
possibility is that ADP-ribosylation inhibitors down-regulate
ApoB-crescents by repressing the structural and functional liaison
between the ER and LDs.
BFA is known to induce mono-ADP-ribosylation of two intracel-
lular proteins, C-terminal-binding protein-1 (CtBP1) short-form/
BFA-ADP-ribosylation substrate (CtBP1-S/BARS) and the glycolytic
enzyme GAPDH [17,18,25,26]. In a previous study, LDs were shown
todecrease either byBFAor CtBP1knockdownand this decreasewas
suppressed by ADP-ribosylation inhibitors [27]. This result led the
authors to speculate that transcription of the genes involved in lipid
synthesis was suppressed by the BFA-induced co-repressor activity
of the long isoform of CtBP1 (CtBP1-L) [27]. The effect of ADP-ribo-
sylation inhibitors thatweobserved in thepresent study is not likely
related to the abovephenomenon, because itwas evidentwithin1 h,
which is too short of a time to affect gene transcription. Consistently,
the ApoB mRNA level was not changed by MIBG, and transcription
inhibition by actinomycinD did not suppress ApoB secretion at least
for 6 h (Figs. S3A, C). On the other hand, the possibility remains that
CtBP1-S/BARS is involved in regulating ApoB-crescent formation
without affecting transcription.
The present results reinforce our contention that the ApoB-cres-
cent is a reliablemarker formonitoring theprocess of lipidatedApoB
accumulation in hepatocytes. The ApoB-crescent is not limited to
hepatocellular carcinoma cell lines, but is also found in human and
mouse primary hepatocytes in culture ([9]; Imai et al., unpublished
observation). The molecular mechanism of ApoB-crescent forma-
tion warrants further studies because it is likely to be related to
the mechanism of intracellular ApoB degradation and the ERLD
relationship. We expect that more molecular insights will be ob-
tained by identiﬁcation of novel ADP-ribosylation targets.
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